Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
CRM
IHD
Cosentyx® - Anti IL-17
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03259074 SURPASS (CAIN457K2340)
Ankylosing spondylitis
Phase 3
837
No radiographic structural progression as measured by modified Stoke Ankylosing
Spondylitis Spine Score (mSASSS)
Secukinumab 150/300 mg
Adalimumab biosimilar 40 mg
Patients with active ankylosing spondylitis
Target Patients
Read-out Milesstone(s)
2022
Publication
Study design manuscript published. Baraliakos et al. Clinical Drug Investigation
(2020) 40:269-278.
NCT03504852 (CAIN457A2324)
Psoriasis
Phase 3B
331
PASI 90 response and IGA mod 2011 0 or 1 response after 16 weeks of treatment
Secukinumab 300 mg every 2 weeks after weekly doses till Week 4
Secukinumab 300 mg every 4 weeks after weekly doses till Week 4
Subjects (≥90kg) with moderate to severe plaque psoriasis
Q3-2020 (actual)
Publication (primary efficacy) in Q3-2021 (ongoing)
Publication of 52-week planned in Q4-2021 (planned)
Abstract at AAD in Q2-2021 Reich K. et al Presented at 2021 AAD VMX (LBA).
Selected to be highlighted in the AAD "Meeting News",
74 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation